• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ArriVent BioPharma, Inc. - Common Stock (NQ: AVBP )

    18.58 +0.31 (+1.70%)
    Streaming Delayed Price Updated: 1:53 PM EDT, Jul 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 31,865
    Open 18.33
    Bid (Size) 17.74 (1)
    Ask (Size) 18.58 (4)
    Prev. Close 18.27
    Today's Range 17.65 - 18.58
    52wk Range 14.35 - 25.95
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
    Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
    Via Talk Markets
    AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024
    AVBP stock results show that ArriVent BioPharma beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -7.10%
    -7.10%
    1 Month
    +1.36%
    +1.36%
    3 Month
    +1.53%
    +1.53%
    6 Month
    -7.10%
    -7.10%
    1 Year
    -7.10%
    -7.10%

    More News

    Read More
    ArriVent BioPharma Reports First Quarter 2024 Financial Results
    From ArriVent BioPharma, Inc.
    Via GlobeNewswire
    ArriVent Appoints Kristine Peterson to its Board of Directors
    From ArriVent BioPharma, Inc.
    Via GlobeNewswire
    ProfoundBio Discovers The Joys Of Having A Wealthy Owner
    Via Benzinga
    Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
    Via Talk Markets
    $10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
    Via Benzinga
    KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.